arrow
R

Rodabe N. Amaria

The University of Texas MD Anderson Cancer Center
H指数:45
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials

可调控膜结合IL-15工程化TIL细胞疗法治疗免疫检查点抑制剂耐药性晚期黑色素瘤:1期和1/2期试验的合并分析

2026-11-030
OAAI
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
TPRG-07 PHASE II STUDY OF NIVOLUMAB (NIVO) IN COMBINATION WITH RELATLIMAB (RELA) IN PATIENTS WITH ACTIVE MELANOMA BRAIN METASTASES (MBM)

TPRG-07 尼鲁单抗(NIVO)联合 relatlimab(RELA)治疗活动性黑色素瘤脑转移(MBM)患者的Ⅱ期研究

2026-08-070
OA
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

新辅助PD-1和LAG-3靶向双特异性抗体与其他免疫检查点抑制剂联合治疗可切除黑色素瘤:随机Ib/II期Morpheus-Melanoma试验

2025-09-240
OAAI
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

Fdg-pet与黑色素瘤新辅助免疫治疗的病理反应和生存率的关系

2025-03-250
OA
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results (vol 9, pg 898, 2023)
2024-04-220
OAAI
OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma
2024-04-050
PRE
Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma
2024-03-220
PRE
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
2023-05-1622
PRE
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
2023-04-144
PRE
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
2023-03-3032
OAAI
Neoadjuvant relatlimab and nivolumab in resectable melanoma

可切除黑色素瘤的新辅助疗法relatlimab和nivolumab

Nature
IF48.5
2022-10-260
OAAI
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

可切除粘膜黑色素瘤的新辅助检查点抑制剂免疫疗法

2022-10-1730
OAAI